

## PROVENGE (sipuleucel-t) PRIOR AUTHORIZATION FORM

Prior authorization guidelines for **Provenge (sipuleucel-t)** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at <a href="https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx">https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx</a>.

□ New request □ Renewal reque	est # of pages:		Prescriber name:				
Name of office contact:			Specialty:				
Contact's phone number:			NPI:			State license #:	
LTC facility contact/phone:			Street address:				
Beneficiary name:			Suite #:	City/state/zip:			
Beneficiary ID#:	DOB:		Phone:			Fax:	
CLINICAL INFORMATION							
Medication requested: Provenge IV suspension Quantity req			requested:	d: 3 x 250 mL bags other:			
Dose requested:							
Diagnosis:				Dx code ( <i>required</i> ):			
Does the beneficiary have a diagnosis of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer?				Yes Submit documentation of diagnosis or literature supporting the use of Provenge for the beneficiary's diagnosis.			
Is the beneficiary currently taking any opioid analgesics for the treatment of cancerelated pain?					Yes Submit beneficiary's complete current No medication list.		
Will the beneficiary be using concurrent chemotherapy or immunosuppressive agents while using Provenge?					☐Yes Submit beneficiary's complete current medication list and treatment regimen.		
What is the beneficiary's ECOG performance status?				Submit documentation.			
Does the beneficiary have a life expectancy of more than 6 months?				☐Yes Submit documentation.			
Does the beneficiary have evidence of liver metastases?				☐Yes Submit documentation.			
Did the beneficiary have a bilateral orchiectomy?				☐ Yes – Submit documentation. ☐ No – Submit recent testosterone level.			
PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS - PHARMACY DIVISION							
Prescriber Signature:						Date:	

<u>Confidentiality Notice</u>: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.